메뉴 건너뛰기




Volumn 5, Issue 6, 2012, Pages 797-804

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

Author keywords

Pharmacology; Platelet reactivity; Platelets; Prasugrel; Ticagrelor

Indexed keywords

PRASUGREL; TICAGRELOR;

EID: 84873530056     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.112.972323     Document Type: Article
Times cited : (357)

References (34)
  • 4
    • 84855992555 scopus 로고    scopus 로고
    • 2011 accf/aha/scai guideline for percutaneous coronary intervention. A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions
    • American college of cardiology foundation; american heart association task force on practice guidelines; society for cardiovascular angiography and interventionss
    • Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44-e122.
    • (2011) J Am Coll Cardiol , vol.58
    • Levine, G.N.1    Bates, E.R.2    Blankenship, J.C.3    Bailey, S.R.4    Bittl, J.A.5    Cercek, B.6    Chambers, C.E.7    Ellis, S.G.8    Guyton, R.A.9    Hollenberg, S.M.10    Khot, U.N.11    Lange, R.A.12    Mauri, L.13    Mehran, R.14    Moussa, I.D.15    Mukherjee, D.16    Nallamothu, B.K.17    Ting, H.H.18
  • 5
    • 37849002889 scopus 로고    scopus 로고
    • Prasugrel achieves greater and faster p2y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    • Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
    • (2008) Eur Heart J , vol.29 , pp. 21-30
    • Wallentin, L.1    Varenhorst, C.2    James, S.3    Erlinge, D.4    Braun, O.O.5    Jakubowski, J.A.6    Sugidachi, A.7    Winters, K.J.8    Siegbahn, A.9
  • 6
    • 37349111065 scopus 로고    scopus 로고
    • Principle-timi 44 investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
    • Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3    O'Donoghue, M.4    Neumann, F.J.5    Michelson, A.D.6    Angiolillo, D.J.7    Hod, H.8    Montalescot, G.9    Miller, D.L.10    Jakubowski, J.A.11    Cairns, R.12    Murphy, S.A.13    McCabe, C.H.14    Antman, E.M.15    Braunwald, E.16
  • 7
    • 79952817340 scopus 로고    scopus 로고
    • The onset of inhibition of platelet ag-gregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data
    • Zhu B, Effron MB, Kulkarni MP, Li YG, Jakubowski JA, Miller DL, Baker BA, Luo J, Small DS, Winters KJ. The onset of inhibition of platelet ag-gregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. J Cardiovasc Pharmacol. 2011;57:317-324.
    • (2011) J Cardiovasc Pharmacol , vol.57 , pp. 317-324
    • Zhu, B.1    Effron, M.B.2    Kulkarni, M.P.3    Li, Y.G.4    Jakubowski, J.A.5    Miller, D.L.6    Baker, B.A.7    Luo, J.8    Small, D.S.9    Winters, K.J.10
  • 10
    • 77958003916 scopus 로고    scopus 로고
    • Inhibitory effects of ticagre-lor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The plato (platelet inhibition and patient outcomes) platelet substudy
    • Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagre-lor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456-1462.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 1456-1462
    • Storey, R.F.1    Angiolillo, D.J.2    Patil, S.B.3    Desai, B.4    Ecob, R.5    Husted, S.6    Emanuelsson, H.7    Cannon, C.P.8    Becker, R.C.9    Wallentin, L.10
  • 11
    • 79960189314 scopus 로고    scopus 로고
    • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the onset/offset and respond studies
    • Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J. 2011;162:160-165.
    • (2011) Am Heart J , vol.162 , pp. 160-165
    • Bliden, K.P.1    Tantry, U.S.2    Storey, R.F.3    Jeong, Y.H.4    Gesheff, M.5    Wei, C.6    Gurbel, P.A.7
  • 12
    • 84874518805 scopus 로고    scopus 로고
    • P2y12 inhibitors adjunctive to primary pci therapy in stemi: Fighting against the activated platelets
    • December 20, 2011. [Epub ahead of print] Available at Accessed. November 5 2012
    • Alexopoulos D. P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: Fighting against the activated platelets. Int J Cardiol. December 20, 2011. [Epub ahead of print] Available at http://dx.doi.org/10.1016/j.ijcard. 2011.11.088. Accessed. November 5, 2012
    • Int J Cardiol
    • Alexopoulos, D.1
  • 14
    • 60649112469 scopus 로고    scopus 로고
    • Triton-timi 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for st-elevation myocardial infarction (triton-timi 38): Double-blind, randomised controlled trial
    • Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731.
    • (2009) Lancet , vol.373 , pp. 723-731
    • Montalescot, G.1    Wiviott, S.D.2    Braunwald, E.3    Murphy, S.A.4    Gibson, C.M.5    McCabe, C.H.6    Antman, E.M.7
  • 17
    • 84858760413 scopus 로고    scopus 로고
    • Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting
    • FABOLUS PRO Investigators. The fabolus pro (facilitation through aggrastat by dropping or shortening infusion line in patients with st-segment elevation myocardial infarction compared to or on top of prasugrel given at loading dose) trial
    • Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5:268-277.
    • (2012) JACC Cardiovasc Interv , vol.5 , pp. 268-277
    • Valgimigli, M.1    Tebaldi, M.2    Campo, G.3    Gambetti, S.4    Bristot, L.5    Monti, M.6    Parrinello, G.7    Ferrari, R.8
  • 19
    • 79954624013 scopus 로고    scopus 로고
    • Beyond efficacy: Pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
    • Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother. 2011;12:1285-1295.
    • (2011) Expert Opin Pharmacother , vol.12 , pp. 1285-1295
    • Giorgi, M.A.1    Cohen Arazi, H.2    Gonzalez, C.D.3    Di Girolamo, G.4
  • 20
    • 80053630737 scopus 로고    scopus 로고
    • Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel
    • Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J. 2011;162:733-739.
    • (2011) Am Heart J , vol.162 , pp. 733-739
    • Alexopoulos, D.1    Xanthopoulou, I.2    Davlouros, P.3    Plakomyti, T.E.4    Panagiotou, A.5    Mavronasiou, E.6    Hahalis, G.7
  • 22
    • 80052573217 scopus 로고    scopus 로고
    • Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a verifynow p2y12 assay: Impact on thrombosis and safety (gravitas) trial
    • Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132-1137.
    • (2011) Circulation , vol.124 , pp. 1132-1137
    • Price, M.J.1    Angiolillo, D.J.2    Teirstein, P.S.3    Lillie, E.4    Manoukian, S.V.5    Berger, P.B.6    Tanguay, J.F.7    Cannon, C.P.8    Topol, E.J.9
  • 23
    • 38349090725 scopus 로고    scopus 로고
    • Assessment of adp-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment
    • Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;99:121-126.
    • (2008) Thromb Haemost , vol.99 , pp. 121-126
    • Sibbing, D.1    Braun, S.2    Jawansky, S.3    Vogt, W.4    Mehilli, J.5    Schömig, A.6    Kastrati, A.7    Von Beckerath, N.8
  • 25
    • 79952149001 scopus 로고    scopus 로고
    • A pharmacody-namic comparison of prasugrel vs. High-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the optimizing anti-platelet therapy in diabetes mellitus (optimus)-3 trial
    • Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacody-namic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011;32:838-846.
    • (2011) Eur Heart J , vol.32 , pp. 838-846
    • Angiolillo, D.J.1    Badimon, J.J.2    Saucedo, J.F.3    Frelinger, A.L.4    Michelson, A.D.5    Jakubowski, J.A.6    Zhu, B.7    Ojeh, C.K.8    Baker, B.A.9    Effron, M.B.10
  • 27
    • 77955992168 scopus 로고    scopus 로고
    • Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects
    • Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514-1521.
    • (2010) Drug Metab Dispos , vol.38 , pp. 1514-1521
    • Teng, R.1    Oliver, S.2    Hayes, M.A.3    Butler, K.4
  • 28
    • 77958100874 scopus 로고    scopus 로고
    • Plato investigators. Effect of cyp2c19 and abcb1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial
    • Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet.2010;376:1320-1328.
    • (2010) Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1    James, S.2    Storey, R.F.3    Armstrong, M.4    Barratt, B.J.5    Horrow, J.6    Husted, S.7    Katus, H.8    Steg, P.G.9    Shah, S.H.10    Becker, R.C.11
  • 29
    • 0030053912 scopus 로고    scopus 로고
    • Platelet function in acute myocardial infarction treated with direct angioplasty
    • Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229-237.
    • (1996) Circulation , vol.93 , pp. 229-237
    • Gawaz, M.1    Neumann, F.J.2    Ott, I.3    Schiessler, A.4    Schömig, A.5
  • 33
    • 77954468084 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral p2y (12) receptor antagonist, in healthy subjects
    • Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487-496.
    • (2010) Eur J Clin Pharmacol. , vol.66 , pp. 487-496
    • Teng, R.1    Butler, K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.